Condition: Proteinuric Kidney Disease · Sponsor: Vertex Pharmaceuticals Incorporated
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
This description comes directly from the study's public registry record.
Medical Information · 617-341-6777 · medicalinfo@vrtx.com
Always discuss trial participation with your own doctor first.
| Alabama Kidney Research | Alabaster, Alabama, United States | Recruiting |
| EmVenio Research - Mobile Unit - Birmingham | Birmingham, Alabama, United States | Recruiting |
| Cardiology, P.C. | Birmingham, Alabama, United States | Completed |
| Children's Hospital of Alabama | Birmingham, Alabama, United States | Recruiting |
| The Kirklin Clinic - Nephrology | Birmingham, Alabama, United States | Recruiting |
| Nephrology Associates | Fairhope, Alabama, United States | Recruiting |
| Heart Center Research LLC | Huntsville, Alabama, United States | Recruiting |
| Nephrology Consultants, LLC | Huntsville, Alabama, United States | Recruiting |
| Renal Associates of Alabama, LLC | Montgomery, Alabama, United States | Recruiting |
| Arizona Kidney Disease and Hypertension Center - Banner Desert Office | Mesa, Arizona, United States | Withdrawn |
| Arizona Kidney Disease and Hypertension Center - Thomas Office | Phoenix, Arizona, United States | Recruiting |
| Phoenix Children's Hospital, Inc. - Nephrology | Phoenix, Arizona, United States | Completed |
+ 306 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05312879